|Table of Contents|

Efficacy of thalidomide combined with 5-hydroxytryptmine receptor antagonist and dexamethasone for the prevention of chemotherapy induced nausea and vomiting：A retrospective study

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 01
Page:
58-61
Research Field:
Publishing date:

Info

Title:
Efficacy of thalidomide combined with 5-hydroxytryptmine receptor antagonist and dexamethasone for the prevention of chemotherapy induced nausea and vomiting：A retrospective study
Author(s):
Qin Rong; Zhou Yongjing; Zhou Qi; Fan Yu
Oncology Department，Affiliated People’s Hospital of Jiangsu University，Jiangsu Zhenjiang 212002，China.
Keywords:
thalidomide; breast cancer; chemotherapy; nausea; vomiting
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2020.01.014
Abstract:
Objective：To observe the clinical efficacy and adverse reactions of thalidomide combined with 5-hydroxytryptmine receptor antagonist and dexamethasone in the prevention of chemotherapy induced nausea and vomiting in adjuvant chemotherapy breast cancer patients.Methods：72 breast cancer patients who received AC/EC chemotherapy in Affiliated People’s Hospital of Jiangsu University from January，2016 to December，2018，were randomly divided into two groups，37 cases in study group and 35 cases in control group.Both groups were treated with double antiemetic therapy with 5-HT3 receptor antagonist and dexamethasone，and the study group was combined with thalidomide simultaneously.Both groups of acute and delayed nausea and vomiting occurred and adverse reaction were observed.Results：The complete remission rates of acute nausea and vomiting in the study group and control group were 45.9% and 28.6%，and the difference was not statistically significant(P=0.15).The effective rates were 94.6% and 88.6% respectively，and the difference was not statistically significant(P=0.423).The complete remission rates of delayed nausea and vomiting in the study group and control group were 27.0% and 5.7%，and the difference was statistically significant(P=0.025).The effective rates were 97.3% and 65.7% respectively，and the difference was statistically significant(P=0.001).After chemotherapy，the incidence rates of constipation and drowsiness in study group were higher than that in control group，and the difference was statistically significant(P=0.03，P=0.004)，but the incidence rate of insomnia in study group was lower than that in control group，8.1% and 31.4% respectively，and the difference was statistically significant(P=0.017).Conclusion：The triple antiemetic therapy with thalidomide，5-HT3 receptor antagonist and dexamethasone can effectively prevent chemotherapy-induced nausea and vomiting，especially for delayed CINV，in breast cancer patients after modified radical mastectomy，and worthy to be popularized.

References:

［1］Adel N.Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies［J］.Am J Manage Care，2017，23(14)：259-265.
［2］Shankar A，Roy S，Malik A，et al.Prevention of chemotherapy-induced nausea and vomiting in cancer patients［J］.Asian Pac J Cancer Prev，2015，16(15)：6207-6213.
［3］Hesketh PJ，Bohlke K，Kris MG.Antiemetics：American society of clinical oncology clinical practice guideline update summary［J］.J Oncol Pract，2017，13(12)：825-830.
［4］Majem M，Moreno ME，Calvo N，et al.Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists［J］.Support Care Cancer，2011，19(12)：1983-1990.
［5］Zhao J，Jiang K，Li Q，et al.Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China［J］.J Med Econ，2019（7）：1-8.
［6］Brown JC，Ligibel JA.Lifestyle interventions for breast cancer prevention［J］.Curr Breast Cancer Rep，2018，10(3)：202-208.
［7］Rithirangsriroj K，Manchana T，Akkayagorn L.Efficacy of acupuncture in prevention of delayed chemotherapy induced nausea and vomiting in gynecologic cancer patients［J］.Gynecol Oncol，2015，136(1)：82-86.
［8］Rapoport B.The clinical problem of chemotherapy-induced nausea and vomiting［J］.Oncology(Williston Park)，2016，30(8)：763-764.
［9］Pamela Hallquist Viale.Chemotherapy-induced nausea and vomiting：Updates and recommendations［J］.J Adv Pract Oncol，2018，9(2)：150-152.
［10］Feyer P，Jordan K.Update and new trends in antiemetic therapy：The continuing need for novel therapies［J］.Ann Oncol，2011，22(1)：30-38.
［11］Razvi Y，Chan S，McFarlane T，et al.ASCO，NCCN，MASCC/ESMO：A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients［J］.Support Care Cancer，2019，27(1)：87-95.
［12］Aapro M，Molassiotis A，Dicato M，et al.The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting(CINV)：The Pan European Emesis Registry(PEER)［J］.Ann Oncol，2012，23(8)：1986-1992.
［13］Zhu J，Yang Y，Liu S，et al.Anticancer effect of thalidomide in vitro on human osteosarcoma cells［J］.Oncol Rep，2016，36(6)：3545-3551.
［14］Liu Y，Zhang J，Teng Y，et al.Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen：Results of a prospective randomized crossover study［J］.Tumori，2009，95(6)：691-696.
［15］Han Z，Sun X，Jiang G，et al.Thalidomide for control delayed vomiting in cancer patients receiving chemotherapy［J］.J Coll Physicians Surg Pak，2016，26(11)：900-903.
［16］Zhang L，Qu X，Teng Y，et al.Efficacy of thalidomide in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy：A randomized，multicenter，double-blind，placebo-controlled phase III trial(CLOG1302 study)［J］.J Clin Oncol，2017，35(31)：3558-3565.

Memo

Memo:
江苏省科技项目（编号：BE2015666）；江苏省创新团队领军人才基金（编号：QNRC2016446）
Last Update: 1900-01-01